Dr. Li is Vice Chairman of Junshi Biosciences and Chairman of TopAllince Biosciences, responsible for overseas business.

From 1997 to 2010, Dr. Li worked at US Food and Drug Administration (FDA) as a regulatory reviewer and held various positions from Oncology drug team reviewer, senior reviewer/expert reviewer, senior GCP reviewer to team leader, branch chief with increasing responsibilities. Before he joined Junshi Biosciences, Dr. Li was appointed as Vice President and Head of Region Asia Regulatory Affairs and Medical Policy in Sanofi. He has extensive experience and expertise in clinical research and medical product evaluation.

Dr. Li obtained his bachelor’s degree in medicine from Shanghai Medical College of Fudan University, the PRC in July 1984 and his master’s degree in medicine from Shanghai Medical College of Fudan University, the PRC in October 1987. He obtained his Ph.D. degree in preventive medicine from University of lowa, the US in May 1994.

Dr. Zou is responsible for the overall work of the company.

Dr. Zou has nearly 30 years of experience in clinical treatment of tumor, R&D of anti-tumor agents and clinical development of novel drugs. She had been working in the level 3 A hospital as a medical oncologist for 10 years from 1995 – 2005. Then she joined Bayer Healthcare pharmaceutical company and lead the clinical development programs of Sorafenib in China as the clinical trial physician, head of oncology therapeutic team in Bayer China. Then she moved to NJ, USA and worked as the global medical lead of Xofigo in the global medical affairs team in BayerhealtherCare Headquarter. In 2012, she joined Celgene and worked as the director, head of the medical department, China. Prior to joining Junshi Biosciences, she was the Vice President and chief medical officer(CMO) of JIANGSU HENGRUI MEDICINE, CO. LTD.

Dr. Zou was trained by medical oncology in China and got her medical doctor degree in the Naval Medical University.

Mr. Li has about two decades of experience working in pharmaceutical industry. Prior to joining Junshi Biosciences, Mr. Li was a lecturer on pathological anatomy of Shanghai Tiedao University School of Medicine. He also served as the sales director of the Shanghai branch of NOVO Nordisk (China) Pharmaceuticals. and held the positions of manager of East China Region, sales director, assistant to general manager and general manager at Tonghua Dongbao Pharmaceutical. Since June 2019, Mr. Li has been serving as director and general manager of Suzhou Landing Biopharmaceutical., and the responsible person of Shanghai branch office of Suzhou Landing Biopharmaceutical.

Mr. Li obtained his bachelor’s degree in medical science from Shanghai Railway University Medical College in July 1986.

Mr. Zhang was one of the founders of Junshi Biosciences when it was established. Since October 2013, Mr. Zhang has been the legal representative, executive director and general manager of Suzhou Union Biopharm.

Mr. Zhang has over 20 years of experience in the pharmaceutical industry. Prior to joining Junshi Biosciences, he served as a scientific researcher of Viron Therapeutics Inc., Canada, and deputy director in Institute of Biopharmaceuticals of Nanjing Simcere Pharmaceutical Research Institute.

Mr. Zhang obtained his master’s degree in biochemistry from Tsinghua University, PRC in July 1995. He was awarded the first prize of the Shandong district award for invention in 2005.

Dr. Yao is CEO and director of TopAlliance. He took part in the invention of certain registered patents and patents in application in relation to JS002 and JS003 for the company.

Prior to joining Junshi Biosciences, Dr. Yao worked as research fellow at the Johns Hopkins University School of Medicine in the Department of Dermatology, associate research scientist in the Human Translational Immunology Department at Yale University, and senior scientist at Amplimmune Inc., a subsidiary of AstraZeneca, where he was responsible for the tumor immunology and anti-autoimmune diseases antibody project.

Dr. Yao obtained his bachelor’s degree in biotechnology from School of Life Sciences of Peking University, the PRC in June 1998 and his Ph.D. degree in molecular genetics from Albert Einstein College of Medicine, the US in January 2003. Dr. Yao has a number of articles published in journals including Nature Communications, Science Advances, Immunity, Jem, Blood and JI. Dr. Yao is also an inventor of six registered patents or patents in application.

Dr. Wang is responsible for manufacturing quality and related work in Junshi Biosciences.

He has been working in pharmaceutical industry for more than 30 years, with over 20 year experience in CGMP of biologics, and the review, manufacturing, pre-approval inspection, CGMP compliance inspection and supervision of biological products including cellular and gene therapy.

Prior to joining Junshi Biosciences, Dr. Wang was Vice President for Quality (Shanghai) at WuXi Biologics (WuXi). Before that, he was Chief Scientist for Compliance and Inspection at Center for Drug Evaluation (CDE), CFDA, Assistant Country Director at the US FDA’s China Office in the US Embassy, etc.

Dr. Wang received his bachelor’s degree in biochemistry from Nanjing University and Ph.D. in pharmacology and toxicology from Dartmouth Medical School in the US in 1995.

Dr. Li is responsible for overseeing the company’s government affairs.

Dr. Li brings decades of expertise in government affairs, including policy research, government relations, information gathering and analysis, crisis management, and corporate branding. From 2005 to 2014, Dr. Li worked within the Shanghai International Group system, where her work encompassed financial advisory, asset management, direct investment, international mergers and acquisitions, and the establishment of an insurance exchange. Prior to joining Junshi Biosciences, she was Vice President at Greenland Financial Investment Holding Group Co., Ltd., where she oversaw investment, financing, and operations in healthcare and digital finance.

Dr. Li received her bachelor’s degree in Economics from Renmin University of China in 1999, a Ph.D. in Management from Fudan University in 2005, and an EMBA from Tsinghua University PBC School of Finance in 2021.

Dr. Keegan is responsible for the strategy, direction and execution of the company’s clinical development plans.

Dr. Keegan has over three decades of experience as a board-certified medical oncologist, clinical researcher, and regulatory authority at FDA. Prior to joining TopAlliance, Dr. Keegan served at FDA for 30 years, latest as Acting Associate Director of Medical Policy Oncology Center for Excellence (OCE), Office of the commissioner; 16 years as Division Director of Oncology Products; 4 years as Deputy Director Division of Clinical Trial Design and Analysis; 8 years as Chief and Medical officer at Oncology Branch. Prior to FDA, Dr. Keegan was Clinical Assistance Professor and medical oncologist at University of North Carolina at Chapel Hill.

Dr. Keegan received her Bachelor of Science in Biology from University of Illinois Champaign-Urbana. She earned her medical degree from Loyola University Stritch School of Medicine. Dr. Keegan completed her residency in internal medicine at the Loyola University Medical Center, Maywood, Illinois, and her fellowship in medical oncology at Roswell Park Memorial Institute, Buffalo, New York.

Mr. Wang is responsible for overseeing the company’s commercial affairs.

Mr. Wang has extensive experience in sales and management within the oncology field. Prior to joining Junshi Biosciences, he held several positions at Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Qilu Pharmaceutical Group Co., Ltd. During his tenure at Hengrui Pharmaceuticals, his career spanned positions such as Medical Information Specialist, Regional Manager, Provincial Manager, Regional Director, Deputy General Manager of the Group, and General Manager of the Oncology Division. His performance was outstanding, and his achievements included driving compliance transformations, building and managing customer database, establishing interactive system between doctors and patients, and cultivating high-performance teams.

Mr. Wang received his bachelor’s degree from China Agricultural University in 2006 and an EMBA from Fudan University in 2023.